TargetBeta
OPRD1
opioid receptor delta 1 · Opioid receptors
4 programs in company-led studies act on OPRD1, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Naltrexonerule | Orexigen Therapeutics | phase 4 | 425 running | OPRK1, OPRM1 | ChEMBL |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 203 running | OPRK1, OPRM1 | ChEMBL |
| nalmefenerule | H. Lundbeck | phase 4 | 201 running | OPRK1, OPRM1 | ChEMBL |
| cebranopadolrule | Tris Pharma | phase 3 | 182 running | OPRK1, OPRL1, OPRM1, PNOC | ChEMBL |
Conditions their studies are in
- Alcoholism, 2 programs
- Opioid-Related Disorders, 2 programs
- Pruritus, 2 programs
- Acute Pain, 1 program
- Chronic Cough, 1 program
- Chronic Pain, 1 program
- Depression, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Migraine Disorders, 1 program
- Obesity, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 2027cebranopadol · Tris Pharma · phase 3 · NCT07845071
- Mar 1, 2027nalmefene · H. Lundbeck · phase 4 · NCT06733519
- Apr 1, 2027Naltrexone · Orexigen Therapeutics · phase 4 · NCT07433413
- Aug 2027Nalbuphine · Trevi Therapeutics · phase 4 · NCT07868419
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.